Dr. Reddy's Laboratories Limited (RDY)

Market Cap	11.39B +3.6%
Revenue (ttm)	3.58B +3.2%
Net Income	456.99M -24.2%
EPS	0.55 -24.1%
Shares Out	833.71M
PE Ratio	24.92
Forward PE	24.66
Dividend	$0.07 (0.53%)
Ex-Dividend Date	Jul 25, 2025

Volume	723,641
Open	13.55
Previous Close	13.55
Day's Range	13.48 - 13.61
52-Week Range	12.19 - 16.17
Beta	0.29
Analysts	Hold
Price Target	14.03 (+3.16%)
Earnings Date	May 12, 2026

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 27,811
• Stock Exchange: NYSE
• Ticker Symbol: RDY
• Website: https://www.drreddys.com

Financial Performance

In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.

Financial numbers in INR

Analyst Summary

According to 5 analysts, the average rating for RDY stock is "Hold." The 12-month stock price target is $14.03, which is an increase of 3.16% from the latest price.

Price Target

$14.03

(3.16% upside)

Analyst Consensus: Hold